Earnings call on November 04, 2026 to discuss Q2 and half-year FY2026-27 results
The Company will host an earnings call for investors and analysts on Wednesday, November 04, 2026 at 2.30 PM IST to discuss its unaudited financial results for the quarter and half-year ended September 30, 2026.
By ScoutQuest · · 2 min read
- Call Date
- Wednesday, November 04, 2026
- Call Time
- 2.30 PM IST
- Purpose
- discuss its unaudited financial results for the quarter and half-year ended September 30, 2026
An earnings call has been announced: what it means
The Company has informed the exchanges that it will hold an earnings call with investors and analysts. This is a scheduled interaction where management discusses its results and takes questions.
Call details
- Date: Wednesday, November 04, 2026
- Time: 2:30 PM IST, with the call slotted from 2:30 to 3:30 PM IST
- Purpose: to discuss the unaudited financial results for the quarter and half-year ended September 30, 2026
The Company
The update is issued by Evonile Pharma Limited, formerly known as Novartis India Limited. The communication is signed by Chandni Maru, Company Secretary and Compliance Officer. Management contacts listed for the call are Bhagwat Singh Deora, Chief Financial Officer, and Jason D'Souza, President – BD, M&A and IR.
How to join
- Participants can pre-register through the Diamond Pass link given in the update. On registering, they receive the dial-in numbers, passcode and pin on the registered email address.
- Universal Dial-in Number (India): +91 22 6280 1488 / +91 22 7115 8869
- Hong Kong Local Access Number: 800 964 448
- Singapore Local Access Number: 800 101 2045
- UK Local Access Number: 0 808 101 1573
- USA Local Access Number: 1 866 746 2133
- Investors and analysts can also register and join through the Company's website, www.evonilepharma.com.
What to note
The update states that the schedule of the meeting may change due to exigencies. Investors who wish to listen in should therefore check the pre-registration link or the Company's website closer to the date.
What this announcement is, and is not
This communication is about the logistics of the call. The financial results themselves are the subject of the call and are not part of this intimation. The call gives retail investors a chance to hear management discuss the quarter and half-year ended September 30, 2026 directly.
Also from Evonile Pharma
Evonile Pharma reports first results after change of control
3 Nov 2026
Evonile Pharma Q2 and H1 FY27 results update: Q2 revenue down 38% YoY after business-model change
3 Nov 2026
Board approves unaudited results for September 2026 quarter; auditors' limited review unmodified
3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.